ProfileGDS5678 / 1450813_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 29% 51% 60% 25% 28% 24% 27% 10% 27% 30% 31% 36% 30% 30% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6966829
GSM967853U87-EV human glioblastoma xenograft - Control 23.2187751
GSM967854U87-EV human glioblastoma xenograft - Control 33.6106960
GSM967855U87-EV human glioblastoma xenograft - Control 42.5298225
GSM967856U87-EV human glioblastoma xenograft - Control 52.5872228
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6290424
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6713927
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.2425610
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5886827
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6732630
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6968831
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7828536
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6739430
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6725830